Page contents Key factsDecisionKey facts Active Substance moxonidine Therapeutic area Cardiovascular diseases Decision number P/0228/2018 PIP number EMEA-002275-PIP01-17 Pharmaceutical form(s) Film-coated tablet Condition(s) / indication(s) Treatment of hypertension Route(s) of administration Oral use Contact for public enquiries Abbott Laboratories LimitedTel. +44 (0) 1628 644513E-mail: robyn.hall@abbott.com Decision type RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) Decision date 29/07/2018DecisionP/0228/2018: EMA decision of 29 July 2018 on the refusal of a product specific waiver for moxonidine (EMEA-002275-PIP01-17)AdoptedReference Number: EMA/480848/2018 English (EN) (65.44 KB - PDF)First published: 28/11/2018ViewShare this page